Prev: Plants Prevent DNA Damage
Next: Rabbit Food and Atherosclerosis
From: ironjustice on 18 Jun 2008 13:24
These overlapping disease states seem to have more in common than
symptoms?
Aplastic anemia .. hemolysis .. fatigue.

http://www.medicalnewstoday.com/articles/111627.php

Epratuzumab Reduced Disease Activity And Steroid Use In Patients With
Moderate And Severe Flaring SLE
Main Category: Lupus
Also Included In: Clinical Trials / Drug Trials
Article Date: 18 Jun 2008 - 1:00 PDT

UCB has announced that data presented recently show that epratuzumab
treatment demonstrated clinically meaningful improvements in moderate
and severe flaring systemic lupus erythematosus (SLE) patients. The
data were from the first placebo-controlled studies using epratuzumab
in SLE patients and were presented at the annual European Congress of
Rheumatology (EULAR).
--------------------------------------------

http://www.medicalnewstoday.com/articles/111618.php

Soliris® Improved Fatigue Independent Of Changes In Anemia In Patients
With PNH By Controlling Hemolysis
Main Category: Blood / Hematology
Article Date: 18 Jun 2008 - 1:00 PDT

Soliris® (eculizumab) therapy improved the often disabling fatigue
experienced by patients with the rare blood disorder paroxysmal
nocturnal hemoglobinuria (PNH) independent of improvements in anemia,
according to data presented at the European Hematology Association
(EHA) 13th Congress in Copenhagen. These data suggest that fatigue
experienced by patients with PNH is related directly to hemolysis -
the red blood cell destruction that defines the disease - and can be
improved independent of correction of anemia.

Who loves ya.
Tom


Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh


Man Is A Herbivore!
http://tinyurl.com/a3cc3


DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
From: ironjustice on 24 Jun 2008 15:23
On Jun 18, 10:24 am, "ironjust...(a)aol.com" <ironjust...(a)aol.com>
wrote:Aplastic anemia .. hemolysis .. fatigue <<

This could be retitled "How to produce aplastic anemia" ..

Ramping up red blood cell production causes apastic anemia.
Do too many red blood cells cause aplastic anemia?

Titre du document / Document title
Anti-erythropoietin antibody-mediated pure red cell aplasia after
treatment with recombinant erythropoietin products: Recommendations
for minimization of risk
Auteur(s) / Author(s)
COURNOYER Denis (1) ; TOFFELMIRE Edwin B. (2) ; WELLS George A. (3) ;
BARBER Dwayne L. (4) ; BARRETT Brendan J. (5) ; DELAGE Robert (6) ;
FORREST Donna L. (7) ; GAGNON Raymonde F. (8) ; HARVEY Elizabeth A.
(9) ; LANEUVILLE Pierre (10) ; PATTERSON Bruce J. (11) ; POON Man-Chiu
(12) ; POSEN Gerald A. (13) ; MESSNER Hans A. (11) ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)
(1) Departments of Medicine and Oncology, McGill University Health
Centre, Montreal, Quebec, ETATS-UNIS
(2) Departments of Medicine, and Pharmacology and Toxicology, Queen's
University, Kingston, Ontario, ETATS-UNIS
(3) Department of Epidemiology and Community Medicine, University of
Ottawa, Ottawa, Ontario, ETATS-UNIS
(4) Ontario Cancer Institute, Toronto, Ontario, ETATS-UNIS
(5) Division of Nephrology, Health Sciences Centre, St. John's,
Newfoundland, ETATS-UNIS
(6) Department of Hematology, CHAUQ, Laval University, Quebec, Quebec,
CANADA
(7) Department of Medicine, University of British Columbia, Vancouver,
British Columbia, CANADA
(8) Division of Nephrology, McGill University Health Centre, Montreal,
Quebec, ETATS-UNIS
(9) Division of Nephrology, Hospital for Sick Children, Toronto,
Ontario, ETATS-UNIS
(10) Division of Hematology, McGill University Health Centre,
Montreal, Quebec, ETATS-UNIS
(11) University Health Network, Princess Margaret Hospital, Toronto,
Ontario, ETATS-UNIS
(12) Department of Medicine, University of Calgary and Foothills
Hospital, Calgary, Alberta, ETATS-UNIS
(13) Division of Nephrology, The Ottawa Hospital, Ottawa, Ontario,
CANADA

Résumé / Abstract
Since 1998, there has been a marked increase in incidence of pure red
cell aplasia secondary to development of anti-erythropoietin
antibodies (Ab+ PRCA) in patients who have chronic kidney disease
(CKD) and receive recombinant erythropoietin. The relationship between
incidence of Ab+ PRCA and specific erythropoietin products has not
been examined rigorously. Manufacturers provided data regarding
exposure to erythropoietin products and incidence of Ab+ PRCA between
January 1998 and March 2003 in patients with CKD. Assuming a Poisson
distribution, a maximum likelihood estimate for the Poisson rate
parameter was calculated for each product. A test for homogeneity of
Poisson rates was conducted to compare likelihood estimates between
products. Global incidence of Ab+ PRCA was relatively low. Likelihood
estimates were not significantly different for Epogen, Procrit, and
Aranesp, independent of their formulation or route of administration.
Eprex lacking human serum albumin (HSA) and administered
subcutaneously was associated with the greatest risk of Ab+ PRCA. HSA-
containing Eprex administered subcutaneously was associated with a
lower risk than HSA-free Eprex administered subcutaneously, but this
risk exceeded that of intravenous Epogen and intravenous HSA-free
Eprex. NeoRecormon administered subcutaneously was associated with
less risk than subcutaneous HSA-free Eprex but more risk than
intravenous Epogen. HSA-free Eprex should not be administered
subcutaneously to patients with CKD due to increased risk of Ab+ PRCA.
Although the subcutaneous administration of HSA-containing Eprex is
riskier than intravenous Epogen and intravenous HSA-free Eprex, and
the use of subcutaneous NeoRecormon is riskier than intravenous
Epogen, there is currently no evidence that other products are safer.
Revue / Journal Title
Journal of the American Society of Nephrology ISSN 1046-6673 CODEN
JASNEU
Source / Source
2004, vol. 15, no10, pp. 2728-2734 [7 page(s) (article)] (28 ref.)
Langue / Language
Anglais

Editeur / Publisher
Lippincott Williams & Wilkins, Hagerstown, MD, ETATS-UNIS (1990)
(Revue)

Mots-clés anglais / English Keywords
Aplastic anemia ; Hemopathy ; Polypeptide ; Nephrology ;
Erythroblast ; Urology ; Risk ; Risk factor ; Recommendation ;
Product ; Treatment ; Antibody ; Erythropoietin ; Pure red cell
aplasia ;
Mots-clés français / French Keywords
Anémie aplasique ; Hémopathie ; Polypeptide ; Néphrologie ;
Erythroblaste ; Urologie ; Risque ; Facteur risque ; Recommandation ;
Produit ; Traitement ; Anticorps ; Erythropoïétine ;
Erythroblastopénie ;
Mots-clés espagnols / Spanish Keywords
Anemia aplástica ; Hemopatía ; Polipéptido ; Nefrología ;
Eritroblasto ; Urología ; Riesgo ; Factor riesgo ; Recomendación ;
Producto ; Tratamiento ; Anticuerpo ; Eritropoyetina ;
Eritroblastopenia ;
Localisation / Location
INIST-CNRS, Cote INIST : 26049, 35400012230448.0230


Copyright 2007 INIST-CNRS. All rights reserved

Toute reproduction ou diffusion même partielle, par quelque procédé ou
sur tout support que ce soit, ne pourra être faite sans l'accord
préalable écrit de l'INIST-CNRS.
No part of these records may be reproduced of distributed, in any form
or by any means, without the prior written permission of INIST-CNRS.

Nº notice refdoc (ud4) : 16146353


Who loves ya.
Tom


Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh


Man Is A Herbivore!
http://tinyurl.com/4rq595


DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk


> These overlapping disease states seem to have more in common than
> symptoms?
> Aplastic anemia .. hemolysis .. fatigue.
>
> http://www.medicalnewstoday.com/articles/111627.php
>
> Epratuzumab Reduced Disease Activity And Steroid Use In Patients With
> Moderate And Severe Flaring SLE
> Main Category: Lupus
> Also Included In: Clinical Trials / Drug Trials
> Article Date: 18 Jun 2008 - 1:00 PDT
>
> UCB has announced that data presented recently show that epratuzumab
> treatment demonstrated clinically meaningful improvements in moderate
> and severe flaring systemic lupus erythematosus (SLE) patients. The
> data were from the first placebo-controlled studies using epratuzumab
> in SLE patients and were presented at the annual European Congress of
> Rheumatology (EULAR).
> --------------------------------------------
>
> http://www.medicalnewstoday.com/articles/111618.php
>
> Soliris® Improved Fatigue Independent Of Changes In Anemia In Patients
> With PNH By Controlling Hemolysis
> Main Category: Blood / Hematology
> Article Date: 18 Jun 2008 - 1:00 PDT
>
> Soliris® (eculizumab) therapy improved the often disabling fatigue
> experienced by patients with the rare blood disorder paroxysmal
> nocturnal hemoglobinuria (PNH) independent of improvements in anemia,
> according to data presented at the European Hematology Association
> (EHA) 13th Congress in Copenhagen. These data suggest that fatigue
> experienced by patients with PNH is related directly to hemolysis -
> the red blood cell destruction that defines the disease - and can be
> improved independent of correction of anemia.
>
> Who loves ya.
> Tom
>
> Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh
>
> Man Is A Herbivore!http://tinyurl.com/a3cc3
>
> DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk

 | 
Pages: 1
Prev: Plants Prevent DNA Damage
Next: Rabbit Food and Atherosclerosis